State Street
STOK icon

State Street’s Stoke Therapeutics STOK Stock Holding History

State Street’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.3M Buy
2,852,240
+575,728
+25% +$18.5M ﹤0.01% 1529
2026
Q1 		$74.1M Sell
2,276,512
-221,537
-9% -$7.27M ﹤0.01% 1544
2025
Q4 		$79.3M Buy
2,498,049
+1,072,176
+75% +$32.2M ﹤0.01% 1484
2025
Q3 		$33.5M Sell
1,425,873
-61,283
-4% -$1.05M ﹤0.01% 1954
2025
Q2 		$16.9M Sell
1,487,156
-88,127
-6% -$837K ﹤0.01% 2282
2025
Q1 		$10.5M Sell
1,575,283
-12,380
-0.8% -$115K ﹤0.01% 2502
2024
Q4 		$17.5M Sell
1,587,663
-141,225
-8% -$1.73M ﹤0.01% 2296
2024
Q3 		$21.2M Buy
1,728,888
+137,145
+9% +$1.94M ﹤0.01% 2172
2024
Q2 		$21.5M Buy
1,591,743
+1,012,136
+175% +$13.7M ﹤0.01% 2131
2024
Q1 		$7.82M Buy
579,607
+36,074
+7% +$219K ﹤0.01% 2718
2023
Q4 		$2.86M Sell
543,533
-42,475
-7% -$182K ﹤0.01% 3184
2023
Q3 		$2.31M Buy
586,008
+34,326
+6% +$226K ﹤0.01% 3267
2023
Q2 		$5.86M Buy
551,682
+130,054
+31% +$1.38M ﹤0.01% 2922
2023
Q1 		$3.51M Buy
421,628
+7,879
+2% +$71.1K ﹤0.01% 3120
2022
Q4 		$3.82M Buy
413,749
+2,259
+0.5% +$23.5K ﹤0.01% 3159
2022
Q3 		$5.28M Buy
411,490
+29,384
+8% +$468K ﹤0.01% 3033
2022
Q2 		$5.05M Sell
382,106
-571,919
-60% -$8.69M ﹤0.01% 3098
2022
Q1 		$20.1M Buy
954,025
+157,173
+20% +$3.15M ﹤0.01% 2398
2021
Q4 		$19.1M Sell
796,852
-117,819
-13% -$2.81M ﹤0.01% 2503
2021
Q3 		$23.3M Buy
914,671
+9,835
+1% +$274K ﹤0.01% 2374
2021
Q2 		$30.5M Buy
904,836
+157,548
+21% +$5.57M ﹤0.01% 2214
2021
Q1 		$29M Buy
747,288
+313,180
+72% +$17.8M ﹤0.01% 2120
2020
Q4 		$26.9M Buy
434,108
+204,696
+89% +$9.38M ﹤0.01% 2049
2020
Q3 		$7.68M Sell
229,412
-37,727
-14% -$1.08M ﹤0.01% 2581
2020
Q2 		$6.37M Sell
267,139
-27,142
-9% -$644K ﹤0.01% 2642
2020
Q1 		$6.74M Buy
294,281
+124,537
+73% +$3.08M ﹤0.01% 2483
2019
Q4 		$4.81M Buy
169,744
+30,765
+22% +$774K ﹤0.01% 2868
2019
Q3 		$2.99M Buy
+138,979
New +$3.88M ﹤0.01% 3061

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street's STOK Position: Q2 2026 in Review

State Street increased its Stoke Therapeutics (STOK) stake by 25% in Q2 2026, buying an estimated $18.5M and bringing the position to 2,852,240 shares worth $93.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

State Street first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • State Street held 2,852,240 shares of Stoke Therapeutics worth $93.3M as of Q2 2026.
  • State Street bought 575,728 Stoke Therapeutics shares in Q2 2026, an estimated $18.5M.
  • Stoke Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1529 holding.
  • State Street first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.